WHO sends Panacea to remediation

It's time to revise the revenue projections at Panacea Biotech. The World Health Organization, following a late June manufacturing plant inspection, has removed three of the drugmaker's combination vaccines from its pre-qualification list, meaning the WHO won't buy its drugs due to the sub-par manufacturing practices observed.

Inspectors found quality management deficiencies at Panacea's vaccine plant near Punjab, India. The vaccines in question include combinations of diphtheria, pertussis, tetanus, Hepatitis B and Hib B. Their final disposition awaits a decision on their acceptability for distribution by the United Nations, which will be made by a WHO-convened committee.

Panacea said the company has begun corrective measures and expects to soon apply for re-listing of the drugs. There are reportedly no quality issues with the vaccines already in the market.

The news is a blow to the vaccine industry in India, which Unicef named the low-cost supplier in most categories following a survey of supplier pricing data that the organization made public for the first time in June. Findings revealed nearly a $1 spread in the 2010 price for one vaccine sourced from 5 suppliers.

- here's the story

Suggested Articles

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.

Eli Lilly is investing $400 million in its Indianapolis site to expand production of insulin and other diabetes meds, and add 100 jobs.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.